目的 探讨金酸萍颗粒联合替诺福韦治疗慢性乙型肝炎的临床疗效。方法 选取2021年11月-2023年2月海南医学院第一附属医院收治的慢性乙型肝炎患者120例,随机法分为对照组(60例)和治疗组(60例)。对照组患者口服富马酸替诺福韦二吡呋酯片,1片/次,1次/d。在对照组的基础上,治疗组口服金酸萍颗粒,15 g/次,1次/d。两组连续服用药12周。观察两组患者临床疗效,比较治疗前后两组患者症状改善时间,生活质量评分,肝功能丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、总胆红素(TBIL)和谷氨酰转肽酶(GGT)指标,及血清炎性因子白细胞介素-17(IL-17)、转化生长因子-β1(TGF-β1)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)水平。结果 治疗后,治疗组患者临床总有效率为98.33%,明显高于对照组(85.00%,P<0.05)。治疗后,治疗组症状改善时间均早于对照组(P<0.05)。治疗后,两组患者的生活质量改善QOL-C30评分明显升高(P<0.05),且治疗组QOL-C30评分明显高于对照组(P<0.05)。治疗后,两组患者ALT、AST、TBIL、GGT、TGF-β1、IL-17、TNF-α、IL-6水平指标均明显下降(P<0.05),且治疗组患者指标水平均明显低于对照组(P<0.05)。结论 金酸萍颗粒联合替诺福韦治疗慢性乙型肝炎效果确切,可明显改善临床症状,有效调节肝功能状态,并减弱机体炎性反应,患者生活质量提高。

Objective To explore the clinical study of Jinsuanping Granules combined with tenofovir in the treatment of chronic hepatitis. Methods Patients (120 cases) with chronic hepatitis in the First Affiliated Hospital of Hainan Medical university from November 2021 to February 2023 were randomly divided into control (60 cases) and treatment (60 cases) group. Patients in the control group were po administered with Tenofovir Disoproxil Fumarate Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Jinsuanping Granules on the basis of the control group, 15 g/time, once daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluation was evaluated, and the improvement time of symptom, quality of life score, the liver function indicators ALT, AST, TBIL and GGT, the serological levels of TGF-β1, IL-17, TNF-α and IL-6 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 98.33%, which was significantly higher than that of the control group (85.00%, P < 0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the QOL-C30 score of quality of life improved significantly in two groups (P < 0.05), and the QOL-C30 score in the treatment group was significantly higher than that in the control group (P < 0.05). After treatment, the levels of ALT, AST, TBIL GGT, TGF-β1, IL-17, TNF-α and IL-6 in two groups were significantly lower than those before treatment (P < 0.05), and the levels of these indexes in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Jinsuanping Granules combined with tenofovir in treatment of chronic hepatitis is effective, which can obviously improve the clinical symptoms, effectively regulate the liver function, weaken the inflammatory reaction, and improve the quality of life of the patients.

R978.7

海南省自然科学基金面上项目(819MS122)